Celladon Corporation is a development stage biotechnology company focused on developing treatments for cardiovascular diseases.
Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new biotechnological tools, have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular therapeutics.
Celladon's first generation product enhances calcium cycling in the heart, delivered via a recombinant adeno-associated viral (rAAV) vector, as a treatment for congestive heart failure.
 |
FIRST-EVER GENE THERAPY FOR HEART PATIENTS
The first-ever clinical trial of gene therapy to treat severe heart failure is available at
NewYork-Presbyterian Hospital/Columbia University Medical Center.
Patients enrolled in the multicenter CUPID trial (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) will undergo a minimally invasive cardiac catheterization procedure that will introduce a specially engineered gene that stimulates production of an enzyme necessary for the heart to pump more efficiently.
|
|
